Under your interpretation, what questions would there be for the FDA to ask Teva about labeling? If the FDA takes the position that a carve-out for the STEMI indication is warranted according to H-W, wouldn't the FDA be dictating this rather than asking about it?
Market Data 
Markets 
AI
